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Non-Hodgkin Lymphoma
Introduction
The current standard of treatment for advanced follicular
lymphoma (FL) is immunochemotherapy, which combines
the anti-CD20 monoclonal antibody rituximab with a variety
of multiagent chemotherapy regimens incorporating anthra-
cyclines (e.g. doxorubicin), anthracenediones (e.g. mitox-
antrone), alkylating agents (e.g. cyclophosphamide), or purine
analogues (e.g. fludarabine).1,2 A number of clinical markers
have been proposed as tools for refining survival prognostica-
tion in FL, most of which rely on the features of the tumor
clone.1,2 In contrast, a limited set of biomarkers is available to
predict treatment outcome in patients with this lymphoma.3,4
The activity of drugs employed for the treatment of FL may
be affected by the patient’s genetic background. The anti-
tumor effect of monoclonal antibodies may be modulated by
polymorphisms of the FCg receptors, which are expressed on
cells responsible for antibody-dependent cell-mediated cyto-
toxicity and are devoted to attracting and activating the
immune response against antibody-coated tumor cells.5
While FCg receptor polymorphisms may influence the out-
come of rituximab monotherapy in FL, their role in the con-
text of immunochemotherapy is questionable.6-15 The thera-
peutic activity of doxorubicin may be modulated by a poly-
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Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be
relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCg receptor,
DNA repair and detoxification genes to prognostic stratification of follicular lymphoma treated with
immunochemotherapy. The study was based on 428 patients enrolled in the FOLL05 prospective trial that com-
pared three standard-of-care regimens (rituximab-cyclophosphamide-vincristine-prednisone versus rituximab-
cyclophosphamide-doxorubicin-vincristine-prednisone versus rituximab-fludarabine-mitoxantrone) for the first
line therapy of advanced follicular lymphoma. Polymorphisms were genotyped on peripheral blood DNA samples.
The primary endpoint was time to treatment failure. Polymorphisms of FCGR2A and FCGR3A, which have been
suggested to influence the activity of rituximab as a single agent, did not affect time to treatment failure in the
pooled analysis of the three FOLL05 treatment arms that combined rituximab with chemotherapy (P=0.742,
P=0.252, respectively). These results were consistent even when the analysis was conducted by intention to treat,
indicating that different chemotherapy regimens and loads did not interact differentially with the FCGR2A and
FCGR3A genotypes. The genotype of MLH1, which regulates the genotoxic effect of doxorubicin, significantly
affected time to treatment failure in patients in the rituximab-cyclophosphamide-doxorubicin-vincristine-pred-
nisone arm (P=0.001; q<0.1), but not in arms in which patients did not receive doxorubicin (i.e., the rituximab-
cyclophosphamide-vincristine-prednisone and rituximab-fludarabine-mitoxantrone arms). The impact of MLH1
on time to treatment failure was independent after adjusting for the Follicular Lymphoma International Prognostic
Index and other potential confounding variables by multivariate analysis. These data indicate that MLH1 genotype
is a predictor of failure to benefit from rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone treat-
ment in advanced follicular lymphoma and confirm that FCGR2A and FCGR3A polymorphisms have no impact
when follicular lymphoma is treated with rituximab plus chemotherapy (clinicaltrials.gov identifier: NCT00774826).
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ABSTRACT
morphism of MLH1,16 a molecule that is  involved in the
induction of cell cycle arrest and apoptosis in response to
the DNA damage produced by doxorubicin.17,18 The out-
come of doxorubicin-based chemotherapy is also affected
by functional polymorphisms of CYBA, a subunit of the
NADPH oxidase complex that produces reactive oxygen
species in response to chemotherapy.19,20 The therapeutic
activity of cyclophosphamide is dependent on polymor-
phisms of genes deputed to its detoxification, such as
GSTA1.19
The FOLL05 study compared three standard-of-care reg-
imens for the first-line therapy of advanced FL.21 Patients
were randomized to receive rituximab plus cyclophos-
phamide, vincristine, and prednisone (R-CVP), or ritux-
imab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP), or rituximab plus fludarabine
and mitoxantrone (R-FM). The FOLL05 study showed that
R-CHOP and R-FM are superior to R-CVP in terms of time
to treatment failure (TTF).21
We took advantage of the FOLL05 study to clarify the
role of FCg receptor polymorphism in advanced FL
patients treated with rituximab-based
immunochemotherapy and to assess whether MLH1,
CYBA and GSTA1 polymorphisms selectively predict the
outcome of a specific immunochemotherapy regimen.
Methods
Patients
Peripheral blood samples were prospectively obtained from
428/504 (84.9%) untreated advanced FL patients enrolled in the
multicenter, randomized FOLL05 study (Table 1; Figure 1).21 The
study was designed to assess differences in TTF, which was the
primary endpoint of the FOLL05 study (see Online Supplementary
Appendix).21,22 The REMARK and STREGA guidelines were fol-
lowed throughout this study.23,24 FOLL05 (clinicaltrials.gov identifier:
NCT00774826) was conducted in compliance with the
Declaration of Helsinki, was approved by the appropriate research
ethics committee, required each patient to provide written
informed consent and also included centralization of DNA from
patients’ samples for ancillary studies.
Single nucleotide polymorphism genotyping
Genomic DNA was extracted from peripheral blood samples.
Genotyping of the FCGR2A rs1801274, FCGR3A rs396991,
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Table 1. Clinical features by availability of biological samples for genotypinga.
Available for genotyping Not available for genotyping
(n=428) (n=76)
N. % N. % P
FLIPI 0.401
0-1 76 17.8 11 14.5
2 242 56.5 40 52.6
3-5 110 25.7 25 32.9
Age >60 years 139 32.5 28 36.8 0.456
Male 224 52.3 40 52.6 0.962
ECOG PS >1 12 2.8 2 2.7 0.933
Ann Arbor stage III-IV 391 91.4 70 92.1 0.829
Nodal areas >4 275 64.3 44 57.9 0.289
Extranodal sites >1 159 37.1 37 48.7 0.057
Bone marrow involvement 232 54.2 42 55.3 0.865
Largest involved node >6 cm 116 27.1 18 23.7 0.543
Hemoglobin <12 g/dL 64 15.0 16 21.1 0.180
LDH >ULN 76 17.8 25 32.9 0.002
Beta-2-microglobulin >ULN 189 44.2 35 46.1 0.759
Grading 0.278
1 147 34.3 20 26.3
2 192 44.9 34 44.7
3 56 13.1 12 15.8
Unclassified 33 7.7 10 13.2
Treatment (ITT) 0.124
R-CVP 135 31.6 33 43.5
R-CHOP 143 33.4 22 28.9
R-FM 150 35.0 21 27.6
Complete remission 303 70.8 52 68.4 0.641
3-year TTF 57.3 47.3 0.222
3-year progression-free survival 62.9 51.4 0.128
3-year overall survival 95.8 90.2 0.209
FLIPI: Follicular Lymphoma International Prognostic Index; ULN: upper limit of normal; ITT: intention to treat; ECOG PS: Eastern Cooperative Oncology Group Performance Status,
LDH: lactate dehydrogenase; R-CVP: rituximab, cyclophosphamide, vincristine, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, prednisone; R-FM: rituximab, fludara-
bine, mitoxantrone.
CYBA rs4673, and GSTA1 rs3957357 single nucleotide polymor-
phisms (SNP) was performed on high molecular weight genomic
DNA by SNP minisequencing (ABI Prism SNaPshot Multiplex
kit, Applied Biosystems, Foster City, CA), after validation of this
approach by DNA direct sequencing of each SNP in a pilot panel
of cases (n=40). Genotyping of the MLH1 rs1799977 SNP was
performed on high molecular weight genomic DNA by Sanger
sequencing. Details are provided in the Online Supplementary
Appendix. Quality control of genotyping was performed by repli-
cate sample analysis (100% concordance in replicates for all the
candidate SNP). Deviation of SNP genotype distribution from
the Hardy-Weinberg equilibrium was tested by the χ2 test or
Fisher exact test if appropriate. SNP genotyping was performed
blind to the study endpoint. 
Statistical analysis
TTF, the primary endpoint of the study, was evaluated accord-
ing to the intention-to-treat principle and was defined as the time
from study entry to last follow-up or to the first of the following
events: less than partial remission, a shift to a different therapy for
any reason after at least one cycle of treatment, progressive dis-
ease, relapse, or death.21 Molecular studies were blinded to the
study endpoints. Analysis of TTF was performed by the Kaplan-
Meier method using the log-rank test to assess differences
between genotype groups.25 The false discovery rate was used to
control for multiple statistical testing.26 Cox regression analysis
was used to estimate genotype-specific hazard ratios and 95%
confidence intervals, adjusting for potentially confounding covari-
ates.27 For each SNP genotype, the hazard ratios were generated
using common allele homozygotes as the reference group. For
SNP with ten or fewer minor allele homozygotes, only the combi-
nation of minor allele homozygotes with heterozygotes was ana-
lyzed. If this combined frequency was still less than ten, the SNP
was removed from the analysis. Proportional hazard regression
assumptions were assessed appropriately. Bias corrected c-index,
calibration slope and heuristic shrinkage estimator of the Cox
model were calculated.28 Cox model stability was internally vali-
dated using bootstrapping procedures.29-31 These approaches pro-
vided an estimate of the prediction accuracy of the Cox model to
protect against overfitting. Categorical variables were compared
by the χ2 test and exact test, when appropriate. All statistical tests
were two-sided. Statistical significance was defined as a P value
<0.05 and a q value <0.1. The analysis was performed with SPSS
v.21.0 and with the R statistical package 3.0.1 (http://www.r-
project.org).
Results
FCg receptor polymorphisms have no prognostic 
impact when advanced follicular lymphoma is treated 
with chemoimmunotherapy
The clinical features of the 428 patients with advanced
FL available for SNP genotyping (84.9% of the whole
FOLL05 study cohort; Figure 1) did not differ from those
of the 76 patients not available for genotyping (Table 1).
These data indicate that the lack of biological material for
genotyping was not due to an unintended selection bias.
Out of the 428 genotyped cases, the FCGR2A and
FCGR3A polymorphisms were assessable in 407 and 406
patients, respectively (Figure 1). In the remaining cases,
the quality and/or quantity of genomic DNA prevented its
amplification and sequencing. The distributions of the
FCGR2A and FCGR3A polymorphisms were in Hardy-
Weinberg equilibrium, thus excluding poor genotyping or
population biases (Online Supplementary Table S1). Patients’
characteristics at diagnosis as well as treatment allocation
distributed without significant differences across the three
genotypes of the FCGR2A and FCGR3A polymorphisms
(Online Supplementary Table S2 and S3). 
It was planned that all FL patients enrolled in the
FOLL05 study, independently of the treatment arm, were
to receive eight doses of rituximab combined with
chemotherapy.21 The impact of FCGR2A and FCGR3A
genotypes on the primary clinical endpoint of the study
(i.e. TTF) was, therefore, initially assessed in the whole
study cohort. By pooled analysis of the three treatment
arms, TTF was not influenced by the FCGR2A (P=0.742)
and FCGR3A (P=0.252) genotypes (Table 2; Figure 2).
FCGR2A and FCGR3A genotypes did not influence TTF
either in clinical subgroups defined by disease bulk or
patients' gender, which might affect disease sensitivity to
rituximab, or in groups with different prognoses according
to the Follicular Lymphoma International Prognostic Index
(FLIPI) (Online Supplementary Figures S1, S2 and S3). The
overall response rate also distributed without significant
differences across the three genotypes of the FCGR2A
(P=0.994) and FCGR3A (P=0.606) polymorphisms. By
multivariate analysis, FLIPI and treatment allocation, but
not FCGR2A and FCGR3A genotypes, were independent
predictors of TTF (Table 2), thus confirming that the
FOLL05 study population included in this genotype-phe-
notype association analysis is representative of patients
with advanced FL.
Patients enrolled in the FOLL05 study were randomized
to receive different loads of chemotherapy combined with
rituximab, with the lowest load being in the R-CVP arm.21
In order to verify whether different chemotherapy regi-
mens and loads might interact  differentially with FCGR2A
and FCGR3A genotypes, the impact of these SNP on TTF
was also assessed by treatment arm. However, even when
the analysis was conducted by intention-to-treatment arm,
TTF did not differ according to FCGR2A and FCGR3A
genotypes (Online Supplementary Figure S1 and S2). 
LIke FCg SNP, polymorphisms of GSTA1 and CYBA also
had no role in FL outcome prediction (Online
Supplementary Figure S4).
The genotype of MLH1 is a predictor of R-CHOP 
treatment failure in advanced follicular lymphoma
The MLH1 polymorphism was assessable in 411 FL
MHL1 polymorphisms in FL
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Figure 1. CONSORT diagram representing the number of patients
included in the analysis. BM: bone marrow; PB: peripheral blood.
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Figure 2. Kaplan-Meier
estimates of time to
treatment failure in the
pooled treatment arms
according to FCGR2A
and FCGR3A genotypes.
(A) Comparison of time
to treatment failure
(TTF) between patients
homozygous for the
common FCGR2A
rs1801274 allele (blue
line), patients heterozy-
gous for the FCGR2A
rs1801274 genotype
(yellow line), and
patients homozygous for
the variant FCGR2A
rs1801274 allele (red
line). (B) Comparison of
TTF between patients
homozygous for the
common FCGR3A
rs396991 allele (blue
line), patients heterozy-
gous for the FCGR3A
rs396991 genotype (yel-
low line), and patients
homozygous for the vari-
ant FCGR3A rs396991
allele (red line). P: P val-
ues by log-rank test.
Table 2. Univariate and multivariate analyses for TTF in the whole study cohort.
                                                                               Univariate analysis Multivariate analysis
                                                             HR               LCI                  UCI                   P                                HR               LCI             UCI                 P
FLIPI                                                                                                                                                                                                                                                                     
0-1                                                                    -                       -                          -                           -                                          -                       -                     -                        -
2                                                                    2.78                 1.67                     4.62                  <0.001                                 2.12                 1.09               4.11                 0.025
3-5                                                                 3.92                 2.30                     6.68                  <0.001                                 2.82                 1.14               6.94                 0.024
Age >60 years                                              1.29                 0.97                     1.73                    0.075                                                                                                              
Male                                                               1.00                 0.87                     1.14                    0.963                                                                                                              
ECOG PS >1                                                 2.68                 1.46                     4.92                    0.001                                   2.11                 1.05               4.22                 0.034
Ann Arbor stage III-IV                                1.78                 0.99                     3.18                    0.052                                   1.53                 0.71               3.29                 0.275
Nodal areas >4                                            1.51                 1.12                     2.03                    0.006                                                                                                              
Extranodal sites >1                                    1.56                 1.19                     2.04                    0.001                                   1.35                 0.95               1.93                 0.094
Bone marrow involvement                        1.87                 1.41                     2.49                  <0.001                                 0.96                 0.61               1.50                 0.872
Largest involved node >6 cm                  1.39                 1.03                     1.86                    0.027                                   1.12                 0.76               1.66                 0.553
Hemoglobin <12 g/dL                                1.51                 1.07                     2.14                    0.018                                                                                                              
LDH >ULN                                                    1.51                 1.10                     2.07                    0.010                                                                                                              
Beta-2-microglobulin >ULN                    1.61                 1.23                     2.11                    0.001                                   1.20                 0.79               1.83                 0.372
Treatment (ITT)                                                                                                                                                                                                                                                
R-CVP                                                              -                       -                          -                           -                                          -                       -                     -                        -
R-CHOP                                                       0.59                 0.43                     0.83                    0.002                                   0.52                 0.35               0.76                 0.001
R-FM                                                            0.64                 0.46                     0.88                    0.007                                   0.54                 0.37               0.78                 0.001
FCGR2A rs18011274                                                                                                                                                                                                                                          
AA                                                                    -                       -                          -                           -                                          -                       -                     -                        -
AG                                                                1.12                 0.80                     1.58                    0.486                                   1.03                 0.72               1.47                 0.844
GG                                                                1.00                 0.63                     1.58                    0.988                                   1.06                 0.66               1.68                 0.795
FCGR3A rs396991                                                                                                                                                                                                                                              
TT                                                                    -                       -                          -                           -                                          -                       -                     -                        -
GT                                                                0.82                 0.53                     1.26                    0.371                                   0.91                 0.58               1.42                 0.685
GG                                                                1.51                 0.81                     1.63                    0.429                                   1.32                  0.2                1.89                 0.126
TTF, time to treatment failure; HR: hazard ratio; LCI: 95% lower confidence interval; UCI: 95% upper confidence interval; FLIPI: Follicular Lymphoma International Prognostic Index;
ULN: upper limit of normal; ITT: intention to treat; ECOG PS: Eastern Cooperative Oncology Group Performance Status, LDH: lactate dehydrogenase; R-CVP: rituximab, cyclophos-
phamide, vincristine, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, prednisone; R-FM: rituximab, fludarabine, mitoxantrone. bP-trend. Total number of patients includ-
ed in the multivariate analysis: 406; events: 165; FCGR2A and FCGR3A genotypes were not assessable in 22 cases.
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patients (Figure 1), and its distribution was in Hardy-
Weinberg equilibrium (Online Supplementary Table S1).
Among the drugs utilized in the FOLL05 study, MLH1 is
known to regulate the genotoxic effects of doxorubicin.17,18
According to this biological rationale, the clinical impact
of the MLH1 polymorphism was initially assessed in FL
patients randomized to the R-CHOP arm. Among FL
patients allocated to R-CHOP, characteristics at diagnosis
distributed without significant differences across the three
genotypes of the MLH1 polymorphism, with the sole
exception of a trend towards a more frequent involvement
of more than one extranodal site in patients homozygous
for the variant allele (Online Supplementary Table S4). 
Univariate analysis for TTF, controlled for multiple com-
parisons by false discovery rate testing, identified the
MLH1 polymorphism as a predictor of R-CHOP treatment
failure in advanced FL (P=0.011; q<0.1) (Table 3; Figure
3A). After R-CHOP treatment, FL patients who carried the
homozygous GG variant genotype of MLH1 showed a
significantly lower 3-year TTF (30.3%) compared to
patients who carried the MLH1 AG (3-year TTF: 66.2%)
or AA (3-year TTF: 68.8%) genotypes (P=0.010 and
P=0.003, respectively, in the pairwise comparisons) (Figure
3A). Consistent with the selective involvement of MLH1
in doxorubicin pharmacodynamics, the MLH1 polymor-
phism did not affect the outcome of FL patients treated
with regimens lacking this drug (i.e. R-CVP and R-FM)
(Online Supplementary Figure S3). By multivariate analysis,
FL patients who carried the homozygous GG variant
genotype of MLH1 displayed a 2.8-fold increase in risk of
failing to benefit from R-CHOP (hazard ratio: 2.81; 95%
confidence interval: 1.18-6.73; P=0.020), after adjusting for
clinically relevant covariates including FLIPI, number of
extranodal sites, bone marrow involvement and raised
level of beta-2-microglobulin (Table 3). The increased risk
of failing to benefit from R-CHOP translated into a signif-
icantly shorter overall survival in FL patients harboring the
homozygous GG variant genotype of MLH1 (Figure 3B). 
The genotype of MLH1 predicts reduced benefit from
the addition of doxorubicin to treatments for follicular
lymphoma
The FOLL05 randomized study demonstrated that R-
CHOP significantly improves TTF compared to R-CVP in
patients with previously untreated FL, thus documenting a
relevant clinical benefit when doxorubicin is added to the
R-CVP backbone in this type of lymphoma.21 Consistent
with these clinical data, the addition of doxorubicin to the
R-CVP backbone resulted in a significant improvement in
the 3-year TTF (19% increase; P=0.002) in FL patients har-
boring the common allele of MLH1 (AA and AG geno-
types) (Figure 4A). In contrast, FL patients who carried the
homozygous GG variant genotype of MLH1 (~10% of the
FOLL05 population) did not gain benefit from doxorubicin
(Figure 4B). 
Discussion
This large prospective substudy of the FOLL05 trial,
shows that: (i) FCg receptor polymorphisms do not have a
prognostic impact when advanced FL is treated with
chemoimmunotherapy; and (ii) the MLH1 genotype is a
predictor of failure of R-CHOP treatment in FL. 
Although several small studies in FL have shown that
FCg receptor polymorphisms may be useful in predicting
MHL1 polymorphisms in FL
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Table 3. Univariate and multivariate analyses for TTF in patients treated with R-CHOP.
Univariate analysis Multivariate analysis
HR LCI UCI P HR LCI UCI P
FLIPI
0-1 - - - - - - -
2 1.75 0.80 3.79 0.155 1.27 0.43 3.71 0.654
3-5 2.50 1.09 5.74 0.030 1.35 0.35 5.25 0.660
Age >60 years 1.02 .059 1.76 0.938
Male 0.94 0.73 1.21 0.649
ECOG PS >1 1.12 .027 4.61 0.873
Ann Arbor stage III-IV 1.34 0.54 3.37 0.522
Nodal areas >4 1.51 0.87 2.60 0.138
Extranodal sites >1 1.95 1.17 3.24 0.010 2.54 1.24 5.19 0.010
Bone marrow involvement 1.74 1.02 2.95 0.039 0.87 0.38 1.98 0.745
Largest involved node >6 cm 1.05 0.57 1.92 0.863
Hemoglobin <12 g/dL 1.39 0.72 2.68 0.319
LDH >ULN 1.42 0.79 2.55 0.241
Beta-2-microglobulin >ULN 1.56 0.94 2.60 0.083 1.17 0.56 2.44 0.662
MLH1 rs1799977
AA - - - - - - - -
AG 0.82 0.44 1.53 0.544 0.90 0.48 1.70 0.757
GG 2.89 1.24 6.72 0.014 2.81 1.18 6.73 0.020
TTF: time to treatment failure; HR: hazard ratio; LCI: 95% lower confidence interval; UCI: 95% upper confidence interval; FLIPI: Follicular Lymphoma International Prognostic Index;
ULN: upper limit of normal; ITT: intention to treat; ECOG PS: Eastern Cooperative Oncology Group Performance Status, LDH, lactate dehydrogenase; R-CVP, rituximab, cyclophos-
phamide, vincristine, prednisone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, prednisone; R-FM: rituximab, fludarabine, mitoxantrone. Total number of patients included in
the multivariate analysis: 138; events: 48; MLH1 genotype was not assessable in 22 cases
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522 haematologica | 2015; 100(4)
Figure 3. Kaplan-Meier estimates of time to treatment failure and overall survival in patients randomized to the R-CHOP arm according to the MLH1
rs1799977 genotype. (A) Comparison of time to treatment failure (TTF) between patients homozygous for the common MLH1 rs1799977 allele
(blue line), patients heterozygous for the MLH1 rs1799977 genotype (yellow line), and patients homozygous for the variant MLH1 rs1799977 allele
(red line). (B) Comparison of overall survival (OS) between patients homozygous for the common MLH1 rs1799977 allele (blue line), patients het-
erozygous for the MLH1 rs1799977 genotype (yellow line), and patients homozygous for the variant MLH1 rs1799977 allele (red line). P: P values
by log-rank test; q, q values by false discovery rate.
Figure 4. Kaplan-Meier estimates of time to treatment failure stratified according to the MLH1 rs1799977 genotype and treatment randomization.
(A) Comparison of time to treatment failure (TTF) between R-CHOP (blue line), R-CVP (red line) and R-FM (yellow line) among patients harboring
the MLH1 rs1799977 AA/AG genotype. (B) Comparison of time to treatment failure (TTF) between R-CHOP (blue line), R-CVP (red line) and R-FM
(yellow line) among patients harboring the MLH1 rs1799977 GG genotype. P, P values by log-rank test.
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response to single agent rituximab, their clinical impact in
the setting of immunochemotherapy is still controversial.6-
14 Our study is the most complete prospective examination
of the effects of FCg polymorphisms on the outcome of
advanced FL patients treated with rituximab combined
with chemotherapy. Consistent with the data from the
PRIMA study,15 our analysis definitively indicates that FCg
receptor polymorphisms have no prognostic impact when
advanced FL is treated with chemoimmunotherapy, inde-
pendently of the tumor burden and the type and load of
drugs that are combined with rituximab. Therefore, FCg
SNP must not be further considered and implemented as
biomarkers in the setting of advanced FL treated with
immunochemotherapy. 
The MLH1 polymorphism is a predictor of R-CHOP
treatment failure in advanced FL. Consistent with the
selective involvement of MLH1 in doxorubicin pharmaco-
dynamics,16-18 the MLH1 genotype did not affect the out-
come of FL patients treated with regimens lacking this
drug. The selective association between MLH1 genotype
and outcome after R-CHOP has been clinically validated in
independent retrospective series of lymphoma patients,
including two retrospective cohorts of patients with diffuse
large B-cell lymphoma and this prospective FL series.16
Overall, these notions point to MLH1 genotype as a predic-
tor of R-CHOP failure in B-cell lymphoma. 
The mechanistic explanation of the phenotype observed
in FL patients who carried the homozygous GG variant
genotype of MLH1 remains to be clarified. In other disease
models, the MLH1 rs1799977 polymorphism associates
with reduced MLH1 protein expression in tumor cells.16,32,33
Alternatively, the MLH1 rs1799977 polymorphism might
be in linkage disequilibrium with other functionally rele-
vant SNP of the MLH1 gene,34 suggesting that multiple
variants within the MLH1 locus may contribute to the risk
of treatment failure in FL. 
The association between CYBA and GSTA1 SNP and
outcome of R-CHOP treatment was not replicated in the
current study cohort. It is likely that moderate sample
size, inter-subtype and other genetic heterogeneity, as
well as small true effect sizes account for the lack of repli-
cation. Alternatively, the lack of replication might be the
consequence of the false positive report probability that is
known to affect candidate gene association studies, and
indicates that, at variance with MLH1 rs1799977, neither
CYBA nor GSTA1 SNP represent prognosticators in B-cell
lymphomas treated with R-CHOP.
Despite the limitations imposed by the sample size, our
data provide a signal of reduced benefit from the addition
of doxorubicin to the R-CVP backbone in FL patients har-
boring the homozygous GG variant genotype of MLH1.
Conversely, the MLH1 genotype has no clinical relevance
in FL patients treated with R-FM, which, in turns, seems
equally effective as R-CHOP in the setting of advanced FL.
R-FM might, therefore, represent a suitable initial
chemotherapy approach for FL patients carrying the
homozygous GG variant genotype of MLH1. Replication
of these findings in other cohorts of FL patients will be
necessary to assess their generalizability. 
The FOLL05 study was designed before the establish-
ment of rituximab maintenance as a standard of care for
advanced FL.2 Furthermore, the FOLL05 study did not
include bendamustine-based regimens among its treat-
ment strategies.2 These facts should prompt investiga-
tions aimed at clarifying whether maintenance after ini-
tial R-CHOP or bendamustine-based immunochemother-
apy might abrogate the prognostic impact of the MLH1
genotype. 
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